1. Home
  2. RIGL vs GFR Comparison

RIGL vs GFR Comparison

Compare RIGL & GFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • GFR
  • Stock Information
  • Founded
  • RIGL 1996
  • GFR 2018
  • Country
  • RIGL United States
  • GFR Canada
  • Employees
  • RIGL N/A
  • GFR N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • GFR
  • Sector
  • RIGL Health Care
  • GFR
  • Exchange
  • RIGL Nasdaq
  • GFR Nasdaq
  • Market Cap
  • RIGL 335.5M
  • GFR 318.9M
  • IPO Year
  • RIGL 2000
  • GFR N/A
  • Fundamental
  • Price
  • RIGL $38.85
  • GFR $5.25
  • Analyst Decision
  • RIGL Buy
  • GFR
  • Analyst Count
  • RIGL 5
  • GFR 0
  • Target Price
  • RIGL $38.20
  • GFR N/A
  • AVG Volume (30 Days)
  • RIGL 995.6K
  • GFR 42.0K
  • Earning Date
  • RIGL 08-05-2025
  • GFR 08-06-2025
  • Dividend Yield
  • RIGL N/A
  • GFR N/A
  • EPS Growth
  • RIGL N/A
  • GFR N/A
  • EPS
  • RIGL 5.43
  • GFR 2.05
  • Revenue
  • RIGL $267,921,000.00
  • GFR $516,308,125.00
  • Revenue This Year
  • RIGL $59.93
  • GFR N/A
  • Revenue Next Year
  • RIGL N/A
  • GFR $27.03
  • P/E Ratio
  • RIGL $7.15
  • GFR $2.52
  • Revenue Growth
  • RIGL 105.62
  • GFR N/A
  • 52 Week Low
  • RIGL $12.66
  • GFR $3.81
  • 52 Week High
  • RIGL $43.72
  • GFR $8.16
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 68.57
  • GFR 67.48
  • Support Level
  • RIGL $39.00
  • GFR $4.14
  • Resistance Level
  • RIGL $42.08
  • GFR $5.01
  • Average True Range (ATR)
  • RIGL 2.32
  • GFR 0.25
  • MACD
  • RIGL -0.37
  • GFR 0.07
  • Stochastic Oscillator
  • RIGL 53.26
  • GFR 97.96

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About GFR Greenfire Resources Ltd.

Greenfire Resources Ltd explores, acquires, develops and produces oil and gas in the Canadian energy sector and internationally. Greenfire currently has two producing oil sand assets, Hangingstone Expansion and Hangingstone Demo. The Company has one reportable operating segment which is made up of its oil sands operations based on geographic location : Athabasca oil sands region of Alberta, Canada, nature of the products sold and integration of facilities and operations.

Share on Social Networks: